| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 8,919 | 10,733 | ||
| Marketable debt securities, short-term | 67,337 | 78,211 | ||
| Restricted cash | 1,472 | 1,472 | ||
| Accounts receivable | - | 3,000 | ||
| Prepaid expenses and other current assets | 5,345 | 6,540 | ||
| Total current assets | 83,073 | 99,956 | ||
| Property and equipment, net | 8,460 | 8,924 | ||
| Intangible assets, net | 2,434 | 2,488 | ||
| Operating lease right-of-use asset | 11,637 | 11,847 | ||
| Total assets | 105,604 | 123,215 | ||
| Accounts payable | 9,756 | 9,412 | ||
| Accrued expenses and other current liabilities | 7,996 | 6,698 | ||
| Operating lease liabilities, current portion | 1,630 | 1,568 | ||
| Total current liabilities | 19,382 | 17,678 | ||
| Operating lease liabilities, net of current portion | 17,400 | 17,832 | ||
| Financing lease liabilities, net of current portion | 43 | 62 | ||
| Total liabilities | 36,825 | 35,572 | ||
| Common stock, 0.001 par value per share 190,000,000 shares authorized 62,149,664 and 59,967,814 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 62 | 62 | ||
| Additional paid-in capital | 493,719 | 490,654 | ||
| Accumulated other comprehensive income | 69 | -5 | ||
| Accumulated deficit | -425,071 | -403,068 | ||
| Total stockholders' equity | 68,779 | 87,643 | ||
| Total liabilities and stockholders' equity | 105,604 | 123,215 | ||
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)